Analyst Ratings For Pacira Pharmaceuticals (NASDAQ:PCRX)
Today, Wedbush reiterated its Outperform rating on Pacira Pharmaceuticals (NASDAQ:PCRX) with a price target of $87.00.
There are 1 sell rating, 5 hold ratings, 8 buy ratings on the stock.
The current consensus rating on Pacira Pharmaceuticals (NASDAQ:PCRX) is Buy (Score: 2.50) with a consensus target price of $56.00 per share, a potential 13.82% upside.
Some recent analyst ratings include
- 7/19/2017-Wedbush Reiterated Rating of Outperform.
- 7/14/2017-Cowen and Company Reiterated Rating of Hold.
- On 6/5/2017 David M Stack, CEO, sold 4,311 with an average share price of $43.32 per share and the total transaction amounting to $186,752.52. View SEC Filing
- On 6/5/2017 James S Scibetta, President, sold 1,966 with an average share price of $43.32 per share and the total transaction amounting to $85,167.12. View SEC Filing
- On 6/5/2017 Kristen Marie Williams, CAO, sold 1,877 with an average share price of $43.32 per share and the total transaction amounting to $81,311.64. View SEC Filing
- On 6/5/2017 Lauren Bullaro Riker, VP, sold 601 with an average share price of $43.32 per share and the total transaction amounting to $26,035.32. View SEC Filing
- On 6/5/2017 Scott Braunstein, SVP, sold 768 with an average share price of $43.32 per share and the total transaction amounting to $33,269.76. View SEC Filing
- On 5/15/2017 James S Scibetta, President, sold 20,000 with an average share price of $51.20 per share and the total transaction amounting to $1,024,000.00. View SEC Filing
- On 5/15/2017 Kristen Marie Williams, CAO, sold 21,041 with an average share price of $50.86 per share and the total transaction amounting to $1,070,145.26. View SEC Filing
Recent Trading Activity for Pacira Pharmaceuticals (NASDAQ:PCRX)
Shares of Pacira Pharmaceuticals closed the previous trading session at 49.20 up +0.05 0.10% with 271,291 shares trading hands.